February 26-28, 2018

Boston, USA


Previous Speakers

Expand/Collapse

Academic Speakers

George Church
Professor of Genetics
Harvard Medical School

Day Two

Wednesday February 22nd, 2017

08.35 | Genome Engineering Technologies and Applications

Daniel Anderson
Sam Goldblith Associate Professor
MIT

Day Two

Wednesday February 22nd, 2017

09.35 | In Vivo Delivery of CRISPR/Cas9 Genome Editing

Terence Flotte
Dean of the School of Medicine, Professor of Medical Education
University of Massachusetts Medical School

Day One

Tuesday February 21st, 2017

17.15 | Chair’s Closing Remarks

09.00 | Chair’s Opening Remarks

Day Two

Wednesday February 22nd, 2017

17.05 | Chair’s Closing Remarks

08.30 | Chair’s Opening Remarks

Christian Mueller
Associate Professor, Pediatrics & Gene Therapy Center
University of Massachusetts Medical School

Alexander Marson
Assistant Professor, Microbiology & Immunology
UCSF School of Medicine

Sabine Topka
Research Fellow
Memorial Sloan-Kettering Cancer Center

Day Two

Wednesday February 22nd, 2017

10.05 | Precise Modeling of Germline Variants Associated with Cancer Risk

Omar Abudayyeh
Graduate Student, Feng Zhang’s Lab
Broad Institute

Day One

Tuesday February 21st, 2017

10.00 | An RNA Toolbox: Discovery and Applications of RNA-Targeting CRISPR Systems- In Collaboration with Twist Biosciences

Benjamin Kleinstiver
Instructor, Keith Joung’s Group
Massachusetts General Hospital & Harvard Medical School

David Scott
Graduate Student, Feng Zhang’s Lab
McGovern Broad MIT

Chun-Qing Song
Postdoctoral Associate
University of Massachusetts Medical School

Winston Yan
Graduate Student Feng Zhang’s Lab
McGovern Broad MIT

Shengdar Tsai
Assistant Member
St Jude Children’s Research Hospital

Justin Eyquem
Research Associate
Memorial Sloan Kettering Cancer Center

Manush Mohammed
Research Instructor, Developmental Biology
University of Pittsburgh Medical School

Workshop A

Thursday February 23rd, 2017

09.00 | Non-Traditional Organism Models for Human Disease

James Gagnon
Postdoctoral Fellow, Alex Schier’s Group
Harvard Medical School

Ru Gunawardane
Director of Stem Cells & Gene editing
Allen Institute for Cell Science

Ruwanthi (Ru) Gunawardane is the director of stem cells and gene editing at the Allen Institute for Cell science, where a multi-disciplinary team science approach is used to study the fundamentals of cell behavior. Ru leads a group of researchers creating a collection of highly quality gene edited stem cell lines that are used by the institute to study cell organization and activities through live cell imaging and are also made available to the research community. Ru joined the Allen institute after spending 5 years at Amgen where she developed assays to screen for novel therapeutics in oncology, inflammation, and cardiovascular diseases and help advance the early drug discovery pipeline. Prior to Amgen, Ru worked at Ambit Biosciences where she was part of a small team of scientists that identified and characterized AC220, a potent FLT3 kinase inhibitor that is currently in phase 3 trials for AML. Ru obtained her PhD in Biology from Johns Hopkins University where she studied microtubule nucleation in the Drosophila and Xenopus model systems. She conducted her postdoctoral work with Joan Brugge at the Harvard Medical School where she studied cell migration and invasion in mammary epithelial cells using 3D tissue culture model systems as a model for breast cancer progression.

Jonathan Gootenberg
Graduate Student, Feng Zhang’s Lab
Broad Institute

Day One

Tuesday February 21st, 2017

10.00 | An RNA Toolbox: Discovery and Applications of RNA-Targeting CRISPR Systems- In Collaboration with Twist Biosciences

Pharma/Biotech Speakers

Bill Lundberg
CSO
CRISPR Therapeutics

Day One

Tuesday February 21st, 2017

09.05 | Panel Discussion: Bringing CRISPR into the Clinic: Making CRISPR Therapeutics a Reality

Day Two

Wednesday February 22nd, 2017

16.35 | Understanding the Regulatory Requirements for CRISPR/Cas9 Mediated Therapeutic Development

Megan van Overbeek
Senior Scientist
Caribou Biosciences

Day One

Tuesday February 21st, 2017

09.05 | Panel Discussion: Bringing CRISPR into the Clinic: Making CRISPR Therapeutics a Reality

Day Two

Wednesday February 22nd, 2017

16.05 | DNA Repair Outcomes Following Cas9 Double-Strand Breaks

Scott Burger
Principal
Advanced Cell & Gene Therapy, LLC

Workshop B

Thursday February 23rd, 2017

13.00 | Taking CRISPR/Cas9 to the Clinic: Learnings from Gene Therapy Applications of Gene Editing

Lorenz Mayr
VP & Global Head, Reagents & Assay Development
AstraZeneca

Day One

Tuesday February 21st, 2017

09.05 | Panel Discussion: Bringing CRISPR into the Clinic: Making CRISPR Therapeutics a Reality

Timothy Miller
President & CEO
Abeona Therapeutics

Benjamin Haley
Senior Scientist
Genentech

Marc Hild
Senior Investigator
Novartis Institutes for BioMedical Research

TJ Cradick
Head of Gene Editing
CRISPR Therapeutics

Abraham Scaria
Head of Gene Therapy Research, R&D
Sanofi

Namjin Chung
Head of Functional Genomics, Target Enabling Science & Technology
AbbVie

Devon Shedlock
Director of Immuno-Oncology
Poseida Therapeutics

Mike Certo
Associate Director, Gene Editing
bluebird bio

Solution Provider Speakers

David Grass
Senior Director, Genetic Engineering
The Jackson Laboratory

Jason Potter
Senior Scientist, SynBio R&D
Thermo Fisher Scientific

Day Two

Wednesday February 22nd, 2017

09.05 | Enhanced CRISPR/Cas9-Mediated Precise Genome Editing by Improved Design and Delivery of gRNA, Cas9 Nuclease & Donor DNA

Greg Gocal
Chief Scientific Officer
Cibus

Shawn Shafer
Director of Advanced Genomics
MilliporeSigma

Laura Geuss
Marketing Specialist, CRISPR Services
GenScript

Anja Smith
Director of R&D
Dharmacon (part of GE Healthcare)

Mark Behlke
Chief Scientific Officer
Integrated DNA Technologies

Ben Borgo
Global Senior Product Manager, Diagnostics & Genomics Division
Agilent Technologies

Niels Geijsen
Founder & Scientific Advisor
NTrans Technologies BV